Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

First-in-human study of RAG-01: A novel small activating RNA therapeutic in BCG failure non-muscle invasive bladder cancer (NMIBC) patients.

Laurence Krieger Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16587

e16587 Background: Targeting the p21 WAF1/CIP1 (p21) gene represents a promising yet challenging therapeutic strategy in cancer tr...

MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.

Yi Liu, Sachin Kumar Deshmukh, Yaohua Ma et al. Jun 01, 2025 pp. 570-570 10.1200/jco.2025.43.16_suppl.570

570 Background: Major histocompatibility complex class I (MHC I) plays a critical role in immune surveillance by binding peptides derived from intracellul...

Mortality from ovarian cancer in women of the United States: A 21-year analysis of trends and disparities.

Sai Sushrutha Mudupula Vemula, Hassan Ijaz, Shafiq Ur Rahman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17551

e17551 Background: In the United States, Ovarian cancer ranks 2nd most common gynecological cancer and causes the highest mortality among all the cancers...

NeoCircle: Investigating circulating tumor DNA dynamics as a predictor of survival in primary breast cancer.

Anthony M George, Yilun Chen, Sergii Gladchuk et al. Jun 01, 2025 pp. 3057-3057 10.1200/jco.2025.43.16_suppl.3057

3057 Background: Persistent circulating tumor DNA (ctDNA) detection during neoadjuvant treatment (NAT) of early-breast cancer (EBC) indicates high-risk di...

Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

Yunan Nie, Anna Wurtz, Fangyong Li et al. Jun 01, 2025 pp. 8544-8544 10.1200/jco.2025.43.16_suppl.8544

8544 Background: Immunotherapy with PD1 axis inhibitors is approved for metastatic non-small cell lung cancer (NSCLC). Outside of tumor PD-L1 expression,...

Mortality rate disparities in breast cancer with obesity: Insights from CDC WONDER analysis of two decades.

Maria Qadri, Shafiq Ur Rahman, Muhammad Ibrahim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13030

e13030 Background: Obesity is a significant risk factor for breast cancer, influencing its incidence and progression, and contributing to mortality. Analy...

Evaluating the utility of DNA methylation signatures in tissue and biofluids for lung adenocarcinoma brain metastasis prediction and non-invasive detection.

Jeffrey Zuccato, Yasin Mamatjan, Farshad Nassiri et al. Jun 01, 2025 pp. 2030-2030 10.1200/jco.2025.43.16_suppl.2030

2030 Background: Brain metastases (BM) are common and arise in 30% of lung adenocarcinoma (LUAD) patients. Patients with LUAD that develop BM have signifi...

STARLITE 2: Phase 2 study of nivolumab plus <sup>177</sup> lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( <sup>177</sup> Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Darren R. Feldman, Robert J. Motzer, Andrea Knezevic et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4612

TPS4612 Background: CAIX is a cell surface glycoprotein expressed in &gt; 95% of ccRCC but rarely in normal tissues. Radiolabeling girentuximab, a CAIX-ta...

Performance evaluation of a multi-cancer early detection assay using NMR-based molecular signatures in a multi-center study.

Patrick C. Strasser, Norbert Thumfart, Hansjörg Habisch et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15079

e15079 Background: Cancer is the second leading cause of death worldwide, accounting for over 10 million deaths annually. Despite the proven impact of ear...

Real-time clinical validation of a blood cell-free, mRNA-based GeneVerify test for screening and early diagnosis of prostate cancer.

Sudhir K. Rawal, Smreti Vasudevan, Samson Mani et al. Jun 01, 2025 pp. 3053-3053 10.1200/jco.2025.43.16_suppl.3053

3053 Background: Prostate cancer screening methods, including prostate-specific antigen (PSA) testing, radiological imaging, and pathological assessments,...

The association and impact of radiographic, pathological, and spirometric emphysema on patients with resectable lung adenocarcinoma.

Yixiao Zhang, Lang Lu, Yuhui Zhang Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23250

e23250 Background: Destruction of alveoli structure and lung function are interrelated, however, their correlation and clinical significance have been not...

Fecal microbiota transplantation (FMT) for opioid-induced constipation (OIC): A prospective, multicenter, single-arm, phase II clinical study.

Xiaoying Wang, Yachen Sun, Xiaolin Pu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps12140

TPS12140 Background: Opioids are the cornerstone of cancer pain management. Opioid-Induced Constipation (OIC) is the most common adverse effect of opioid...

The accuracy and efficiency of large language models for chart review in cancer genetics.

James Dickerson, Margaret Shaw, Mina Satoyoshi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22603

e22603 Background: Constructing databases is crucial for answering clinical questions but is time-consuming and error-prone. Our institution has maintaine...

Genomic landscape of Indian DLBCL: Ready for prime time.

Rahul Bhargava, Shrinidhi Nathany, Anusha Swaminathan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23296

e23296 Background: While many studies have explored the mutational landscape of DLBCL, the Indian DLBCL remains relatively unexplored. Studies have shown...

Point-of-care social needs screening and resource navigation for patients with cancer undergoing active treatment: A pilot initiative.

Meera Vimala Ragavan, Christine Shieh, Olga Egorova et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13800

e13800 Background: Patients with cancer undergoing active treatment often face social needs including housing, transportation, food, and financial challen...

Low-pass whole methylome sequencing–based liquid biopsy for metastatic colorectal cancer monitoring in the VALENTINO trial.

Paolo Manca, Marta Paoli, Adele Busico et al. Jun 01, 2025 pp. 3552-3552 10.1200/jco.2025.43.16_suppl.3552

3552 Background: The amount of ctDNA is a proxy for metastatic colorectal cancer (mCRC) disease burden, with potentials for prognostic stratification and...

Evaluation of indocyanine green (ICG) and handheld fluorescence imager in the management of early-stage gynecological cancer.

Shalini Rajaram, Nilotpal Chowdhury, Swati Iyer Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5638

TPS5638 Background: Current management in most early-stage cancers is complete lymphadenectomy for staging. Since surgery is the mainstay of treatment tai...

Preoperative treatment for potentially resectable esophageal cancer: Insights from a nationwide real-world study.

Jie Tang, Hui Lin, Chengli Du et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14598

e14598 Background: In the ASTRUM-007 trial, serplulimab combined with chemotherapy significantly prolonged overall survival (OS) in patients with advanced...

Equivalence of Ina, an AI-based nutrition platform, to human dietitians for counseling patients with cancer.

Marissa Buchan, Mélanie Guirette, Nancy Buderer et al. Jun 01, 2025 pp. 12117-12117 10.1200/jco.2025.43.16_suppl.12117

12117 Background: Addressing nutritional issues in patients with cancer can reduce symptoms, shorten hospitalizations, enhance treatment adherence, and im...

Subsequent treatments and outcomes in bacillus Calmette-Guerin–unresponsive patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ: A real-world data analysis.

Ariel B. Bourla, Ran Sun, Shalaka Hampras et al. Jun 01, 2025 pp. 4604-4604 10.1200/jco.2025.43.16_suppl.4604

4604 Background: Intravesical (ives) Bacillus Calmette-Guerin (BCG) is the recommended first-line treatment (tx) option for patients (pts) with high-risk...

Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by race and ethnicity.

Qian Qin, Nicole Zhang, Jill Tsai et al. Jun 01, 2025 pp. 5077-5077 10.1200/jco.2025.43.16_suppl.5077

5077 Background: Racial/ethnic (R/E) disparities in prostate cancer incidence and outcomes have long been noted. Increasing evidence points to underlying...

Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Yungan Tao, Lillian L. Siu, Lisa F. Licitra et al. Jun 01, 2025 pp. 6013-6013 10.1200/jco.2025.43.16_suppl.6013

6013 Background: In the final efficacy analysis of the randomized, double-blind, phase 3 KEYNOTE-412 trial (NCT03040999),...

Real-world baseline characteristics and diagnostic path of Polish patients with ALK-positive NSCLC eligible for brigatinib treatment: Interim results from the ENTIRETY study.

Katarzyna Magdalena Stencel, Grzegorz Czyżewicz, Tomasz Jankowski et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20640

e20640 Background: In anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (ALK+ NSCLC), early diagnosis, patient characteristics, and ear...

Impact of antiresorptive bone agents in hormone-sensitive metastatic prostate cancer (mHSPC): A meta-analysis.

Gabriel Berlingieri Polho, Adler Melo, Laerte Canedo Ornelas Filho et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17122

e17122 Background: The continuous improvement of survival of mHSPC patients (pts) increases their risk of bone loss. The use of bone modifying agents (BMA...

A zero passage ex-vivosingle cell mass response assay to predict tumor response: An observational analysis in gastrointestinal adenocarcinomas.

Bailey Mendel, Robert Kimmerling, Mark Stevens et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16065

e16065 Background: Gastrointestinal cancer remains a significant challenge due to limited effectiveness of current therapies. Clinical and molecular tumor...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page